Sustainable models: content licensing for generative AI training

​
November 21, 2025

It is fair to say that no technology in recent times has created so much excitement and controversy as generative AI, and in particular Large Language Models (LLMs). Generative AI companies and their backers have their sights on generating billions, if not trillions of dollars, directly or indirectly from their models. Models which, in the vast majority of cases, are trained on original works without permission from, or payment to, their authors. The works used for training are primarily obtained by scraping the open web, a uniquely vast repository of publicly accessible knowledge and information, constantly updated to reflect the latest developments in human knowledge and culture.

Even leaving aside the big questions of what is ethical and what is equitable, it could be argued that the generative AI industry must eventually move from being extractive to being sustainable. The AI companies need a continuing supply original works so that their models can continue to reflect an ever-changing world. And as we move to a world where more and more information is intermediated via LLMs (i.e. “answer engines”, rather than “search engines”), creators need a means of remuneration to enable them to continue creating and sharing their work, which is ultimately in everyone’s interest.

These issues haven’t escaped the scrutiny of the law. Thanks to a largely harmonised copyright system, creative works are by default protected by copyright wherever they are created and wherever they are subsequently used. But that harmony, and the copyright system itself, are now under threat, as different countries and regions, pursuing different policy goals, have started to diverge in their approach to generative AI. In the US – home ground of the most illustrious AI companies – battles are raging in the courts over what constitutes “Fair Use” of copyright works. In the EU, generative AI training has seemingly been grandfathered into a Text and Data Mining (TDM) exception that predates the technology, enabling training on copyright works provided the rightsholder has not explicitly opted out. Publishers and creatives argue that the opt-out is unworkable, while a recent case in Germany (GEMA v OpenAI) suggests that generative AI training can fall outside the TDM exception altogether. Under UK law there is less leeway for use of copyright works, though in a landmark ruling (Getty Images v Stability AI), it was found that importing a model into the UK trained on copyright works was not an infringement. The government is now considering its approach, aiming to balance its ambition to become an AI leader with the interests of its significant creative and media sectors.

Due to the scale of datasets needed for generative AI training (at least in its current guise), it may be unrealistic for AI companies to negotiate licences with each individual rightsholder. This cries out for a collective licensing scheme and a functioning data marketplace, perhaps analogous to that of the music industry. Another analogy is music and video streaming, where content creators are paid per stream. Something similar could potentially work for AI models, though it would require technology for attributing value either to models or outputs at scale. In either case, the volumes of data typically used in AI training could make such solutions costly and challenging to administer.

Collective licensing solutions do not fit well with the current dynamic and automated nature of web-scraping. An alternative, or additional, solution might involve integrating payment into web-scraping itself. During this process, a web-scraper requests a webpage via a URL, loads the HTML of the page (including JavaScript and all elements), and extracts and saves the data it finds. A list of URLs from which data has been extracted will be generated, and this information could be used to trigger payments to an account associated with the URL. This method would however rely on the companies sending out the scrapers to report honestly and transparently on what they have done, something which would be difficult to enforce or police.

Alternatively, web pages could require payment for web-scraper access. For example, software implemented on a web server could detect that a request for content is from a web-scraper, and in response, a payment element may first be returned which, if agreed to, will allow the scraper access to the URL. A solution along these lines has recently been implemented by US infrastructure company Cloudflare, which sits behind around a quarter of all websites. This solution would require less transparency and honesty from the AI companies, but would require operators to implement additional technology on their servers. To the extent that AI training (rather than web-scraping per se) is the relevant act, such a solution would also need to determine that the purpose of the web-scraping is to train an AI model. This may be critical as website owners would still wish to enable web scrapers for indexing by search engines to access their servers unimpeded. In the UK, a proposed amendment to the Data Access and Usage Bill, which would have legally required web-crawlers to be transparent about their purpose, was recently rejected. Innovative technical solutions around detecting and/or authenticating access by different web-crawlers may also be developed.

In our view, the most impactful approach to safeguarding creators’ IP rights is likely to involve a combination of technical and legal solutions. To the extent that courts and governments across the world decide that companies should require permission to use (and hence pay for) copyrighted content to train AI models, there will need to be scalable and workable technical infrastructure to support this. There is innovation in this space. But any technical solutions will work best if backed by strong copyright law. This will ensure that, even where attempts to circumvent the technology are made, there will remain the option of asserting authors’ IP rights in the courts.

‍

The Latest Thought Leadership pieces in the Content Hub

Strategic licensing: Turning IP into commercial value
December 9, 2025
In today’s competitive landscape, effective commercial licensing strategies are essential for unlocking the full value of intellectual property. This article explores four critical pillars: understanding intellectual property as a property right, the fundamentals of licensing intellectual property rights, structuring successful joint ventures and best practices for intellectual property rights management. Whether you’re navigating new markets or scaling established innovations, these tips provide a roadmap for protecting, leveraging and maximizing your IP assets.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
#
Consulting
​
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
#
Consulting
​
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
#
Consulting
​
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
#
Litigation
​
Antibody Patent Protection in Europe and the US: Navigating EPO and USPTO Differences
16 April 2026
This article explores the complexities of patenting antibody therapies, focusing on the differing requirements and practices of the European Patent Office (EPO) and the United States Patent and Trademark Office (USPTO). It highlights how the scope of claims, inventiveness standards, and supporting data requirements vary between jurisdictions, and explains why a tailored IP strategy is essential for innovators especially SMEs seeking protection in both Europe and the US. The article also outlines how EIP’s transatlantic teams collaborate to optimise patent applications for success in these key markets.
#
Patenting
​
Why competitor patent monitoring is critical to your drug development strategy
15 April 2026
This article explains why competitor IP monitoring is a critical part of an effective drug development strategy. By tracking competitor patent activity, companies can assess freedom to operate, identify risks and opportunities early, and make informed decisions on patent filings, licensing, and investment readiness. Ongoing monitoring also supports FTO analysis, third‑party observations, oppositions, and litigation strategy, helping life sciences businesses protect value and reduce risk throughout development.
#
Consulting
​
Biopharma Strategy in 2026: Lessons from 2025 on AI, M&A and the UPC
13 April 2026
This article looks back on a selection of key trends in the (bio)pharma industry in 2025 and looks ahead to how these may continue to develop into 2026.
#
Consulting
​
Thinking about IP from day one: strategic considerations for deep tech startups
08 April 2026
For deep tech startups, intellectual property decisions often come too late or cost too much too soon. This article explores why IP strategy should be considered from day one, even if formal protection comes later. It outlines how founders can decide what to patent, when trade secrets may be more appropriate, and how detectability, enforceability and cost should shape early choices. With a focus on practicality and commercial alignment, it also looks at how newer, AI‑assisted approaches can help startups take a more cost‑effective and flexible approach to building meaningful IP protection.
#
Consulting
​
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
#
Patenting
​
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
#
Patenting
​
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
#
Patenting
​
Provisional Agreement Reached on the EU Pharma Package: Takeaways for Pharmaceutical Companies
17 February 2026
The EU’s new Pharma Package will overhaul regulatory exclusivity, orphan drug incentives, antimicrobial innovation, and generic entry pathways, reducing standard protection periods while introducing new rewards like transferable exclusivity vouchers.
#
Patenting
​
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.
#
Patenting
​
Confidentiality at the UPC: What litigants need to know
21 January 2026
This article explains how the Unified Patent Court approaches confidentiality in litigation, outlining the procedures for restricting access to sensitive information, how confidentiality clubs are formed, and when hearings may be held in private. It highlights key case law shaping these rules, the balance between fair trial rights and protection of commercial data, and the penalties for breaches. Practical guidance is provided to help parties navigate applications, manage confidential documents, and understand what to expect throughout UPC proceedings.
#
Litigation
​
EPO fees are going up in April 2026: Plan ahead now
19 January 2026
The European Patent Office will introduce a fee increase of roughly 5% from 1 April 2026, affecting search, examination, designation and renewal fees. Filing, excess page, opposition and appeal fees remain unchanged. Some costs—such as renewal fees—can be paid up to three months early, allowing applicants to secure the current lower rates. EIP recommends reviewing your portfolio ahead of the deadline.
#
Patenting
​